IOVANCE BIOTHERAPEUTICS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $44.13 million for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-03.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-08-03
- IOVANCE BIOTHERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $25.33M.
- IOVANCE BIOTHERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was $18.80M, a 90.30% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was $25.77M, a 182.51% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was -$16.36M, a 180.38% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $8.89M.
- IOVANCE BIOTHERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$71.21M.
- IOVANCE BIOTHERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$1.59M.
- IOVANCE BIOTHERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$13.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2017-06-30 | $25.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $44.13M 10-Q · filed 2017-08-03 | $69.90M derived: sum of 3 quarters · filed 2017-08-03 | $53.54M derived: sum of 4 quarters · filed 2017-08-03 | ||||
| 2017-03-31 | $18.80M 10-Q · filed 2017-05-03 | $44.57M derived: sum of 2 quarters · filed 2017-05-03 | $28.21M derived: sum of 3 quarters · filed 2017-05-03 | $17.82M derived: sum of 4 quarters · filed 2017-08-03 | ||||
| 2016-12-31 | $25.77M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $9.41M derived: sum of 2 quarters · filed 2017-03-09 | -$986.00K derived: sum of 3 quarters · filed 2017-08-03 | $8.89M 10-K · filed 2017-03-09 | ||||
| 2016-09-30 | -$16.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | -$26.75M derived: sum of 2 quarters · filed 2017-08-03 | -$16.87M 10-Q · filed 2016-11-04 | -$7.75M derived: sum of 4 quarters · filed 2017-08-03 | ||||
| 2016-06-30 | -$10.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$515.00K 10-Q · filed 2017-08-03 | -$314.00K 10-Q · filed 2016-08-09 | $8.61M derived: sum of 3 quarters · filed 2017-08-03 | $28.95M derived: sum of 4 quarters · filed 2017-08-03 | |||
| 2016-03-31 | $9.88M 10-Q · filed 2017-05-03 | -$147.00K 10-Q · filed 2016-05-09 | $19.00M derived: sum of 2 quarters · filed 2017-05-03 | $39.35M derived: sum of 3 quarters · filed 2017-05-03 | -$60.55M derived: sum of 4 quarters · filed 2017-05-03 | |||
| 2015-12-31 | $9.12M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $29.47M derived: sum of 2 quarters · filed 2017-03-09 | -$70.43M derived: sum of 3 quarters · filed 2017-03-09 | -$71.21M 10-K · filed 2017-03-09 | -$91.15M 10-K · filed 2016-03-11 | |||
| 2015-09-30 | $20.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | -$79.55M derived: sum of 2 quarters · filed 2016-11-04 | -$80.33M 10-Q · filed 2016-11-04 | -$100.89M 10-Q · filed 2015-11-06 | -$81.75M derived: sum of 4 quarters · filed 2017-03-09 | |||
| 2015-06-30 | -$99.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$100.68M 10-Q · filed 2016-08-09 | -$100.68M 10-Q · filed 2015-08-10 | -$102.10M derived: sum of 3 quarters · filed 2017-03-09 | -$102.26M derived: sum of 4 quarters · filed 2017-03-09 | |||
| 2015-03-31 | -$782.00K 10-Q · filed 2016-05-09 | -$2.21M derived: sum of 2 quarters · filed 2017-03-09 | -$2.37M derived: sum of 3 quarters · filed 2017-03-09 | |||||
| 2014-12-31 | -$1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | -$1.59M derived: sum of 2 quarters · filed 2017-03-09 | -$1.59M 10-K · filed 2017-03-09 | -$1.59M 10-K · filed 2015-03-16 | ||||
| 2014-09-30 | -$161.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | -$167.00K 10-Q · filed 2015-11-06 | ||||||
| 2014-06-30 | -$5.74K 10-Q · filed 2015-08-10 | |||||||
| 2013-12-31 | -$13.00K 10-K · filed 2016-03-11 | -$12.71K 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |